Antiphospholipid antibodies (aPL) are implicated in approximately a quarter of a million
thrombotic events in the United States annually. These antibodies, anticardiolipin, anti-β2 …

Objective. Antiphospholipid syndrome (APS) is characterized by thrombosis (venous and
arterial) and pregnancy loss in conjunction with the lupus anticoagulant, IgG or IgM …

Although much progress has been made in the past 20 years on understanding the clinical
features of antiphospholipid syndrome (APS), investigation into its epidemiology has been …

The diagnosis of antiphospholipid syndrome is predominantly made in the laboratory and
depends on the persistent presence of antiphospholipid antibodies in individuals with …

The clinical hallmarks of the antiphospholipid syndrome (APS) were described in the early
1980s as vascular thrombosis and pregnancy morbidity. Some of these events, such as …

Publisher Summary This chapter focuses on the classification and prevalence of
antiphospholipid syndrome (APS) in the general population. The classification criteria for the …

The antiphospholipid syndrome (APS) is characterized by venous or arterial thrombosis
and/or pregnancy morbidity in patients with persistent presence of antiphospholipid …

The antiphospholipid syndrome (APS) is defined by the occurrence of venous and arterial
thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses and …

Objective: To determine the risk of antiphospholipid antibody-related disorders in women
with elevated levels of these antibodies. Methods: We used an historic cohort study design …

Antiphospholipid syndrome (APS) is a clinical autoimmune disorder characterized by
thrombosis/pregnancy morbidity associated with the persistence of lupus anticoagulant (LA) …